ArcherDX Blog



Dec
5
2017

Archer at ASH 2017

ArcherDX at the American Society of Hematology in Atlanta, GA from December 9-12, 2017


Nov
14
2017

Press release: ArcherDX receives EN ISO 13485 certification for medical device quality management

ArcherDX announces ISO 13485:2003 & EN ISO 13485:2012 certification indicating that the company’s quality management system maintains standards specific to medical devices, including in vitro diagnostic (IVD) assays


Nov
10
2017

Press release: ArcherDX, Celgene ink CDx development agreement

ArcherDX, Celgene ink worldwide companion diagnostic agreement relating to investigational drug CC-122


Oct
6
2017

ArcherDX at AMP 2017

Boost your molecular pathology research with Archer NGS assays, presenting at AMP 2017, Salt Lake City, UT Nov 16-18, Booth #1619


Oct
5
2017

Webinar - Archer VariantPlex myeloid assays

In this webinar we discuss how updates to the assay and software provide better coverage over challenging regions and enable lower limits of detection, high-resolution CNV detection and lightning-fast analysis that leverage and maximize the unique power of the patented Anchored Multiplex PCR (AMP™) target enrichment chemistry used in Archer NGS assays.


Oct
2
2017

Input considerations for TCR and BCR sequencing

NGS is a powerful method to investigate the immune repertoire, and using RNA as the starting material has several advantages over DNA. Plus, sample-specific cell distributions and cell type-specific mRNA variations should be considered when analyzing the functional immune repertoire to minimize erroneous clonotyping.


Sep
12
2017

Archer® Analysis tool: CNV Visualization in v5.1

The CNV visualization tool within Archer Analysis was designed to maximize analytical capabilities for a variety of NGS library preparations. By giving the user the ability to customize the sensitivity settings based on assay and normalization requirements, copy number gains and losses, in addition to novel variants, can be detected with exon-level resolution and effortlessly tracked within the database.


Sep
8
2017

FLT3-ITD Detection Tech Note

ArcherDX scientists developed Archer® VariantPlex® myeloid assays to detect FLT3-ITDs, along with other myeloid-specific variants, by targeted next-generation sequencing (NGS). A new technical note discusses how Anchored Multiplex PCR (AMP™) chemistry in conjunction with the data-optimized analysis algorithm in Archer Analysis enable accurate detection of FLT3-ITDs across all sizes and insertion sites from clinical-type samples with 100% accuracy.


Aug
14
2017

AMPlify your immune repertoire sequencing

AMP enrichment chemistry and Archer Analysis software reduce PCR bias and minimize PCR and sequencing errors that plague amplicon-based approaches by delivering reliable BCR and TCR sequencing. Immunoverse TCR and BCR kits enable quantitative and sensitive clonotype detection, with sequences detectable at fractions as low as one in a million. Coupled with the fully automated Archer Analysis software and user-owned data, a wide variety of research applications are available to you.


Jul
28
2017

ArcherDX expands blood-based mutation assay portfolio with new myeloid panels

ArcherDX launches two new NGS-based NGS-based variant-detection assays, the 37-gene VariantPlex Core Myeloid and 72-gene VariantPlex Myeloid panel with unprecedented levels of confident mutation detection.

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2017 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.